Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hidradenitis Suppurativa | 9 | 2020 | 309 | 1.15 | Why? |
| Mucous Membrane | 1 | 2020 | 305 | 0.70 | Why? |
| Skin Diseases | 4 | 2020 | 2509 | 0.65 | Why? |
| Dermatology | 6 | 2020 | 1999 | 0.63 | Why? |
| Acne Vulgaris | 3 | 2020 | 198 | 0.50 | Why? |
| Skin | 2 | 2021 | 2096 | 0.44 | Why? |
| Clindamycin | 3 | 2019 | 59 | 0.43 | Why? |
| Drug Eruptions | 2 | 2020 | 319 | 0.28 | Why? |
| Adalimumab | 2 | 2019 | 389 | 0.28 | Why? |
| Antineoplastic Agents, Immunological | 3 | 2019 | 830 | 0.25 | Why? |
| Antipruritics | 2 | 2019 | 15 | 0.24 | Why? |
| Rifampin | 3 | 2019 | 276 | 0.24 | Why? |
| Administration, Cutaneous | 2 | 2020 | 229 | 0.24 | Why? |
| Parapsoriasis | 1 | 2021 | 12 | 0.23 | Why? |
| Pruritus | 2 | 2020 | 215 | 0.22 | Why? |
| Dermatitis, Exfoliative | 1 | 2021 | 50 | 0.21 | Why? |
| Menthol | 1 | 2018 | 6 | 0.20 | Why? |
| Prurigo | 1 | 2019 | 17 | 0.19 | Why? |
| Permethrin | 1 | 2018 | 11 | 0.19 | Why? |
| Camphor | 1 | 2018 | 14 | 0.19 | Why? |
| Phenobarbital | 1 | 2018 | 22 | 0.19 | Why? |
| Cranial Irradiation | 1 | 2018 | 20 | 0.19 | Why? |
| Myiasis | 1 | 2018 | 16 | 0.18 | Why? |
| Balanitis | 1 | 2017 | 4 | 0.18 | Why? |
| Homocysteine | 1 | 2018 | 83 | 0.18 | Why? |
| Scabies | 1 | 2018 | 75 | 0.17 | Why? |
| Glucose Intolerance | 1 | 2018 | 115 | 0.17 | Why? |
| Pemphigoid, Bullous | 1 | 2018 | 89 | 0.17 | Why? |
| Insecticides | 1 | 2018 | 178 | 0.16 | Why? |
| Chlorhexidine | 1 | 2018 | 176 | 0.16 | Why? |
| Thalidomide | 1 | 2019 | 247 | 0.15 | Why? |
| Insulin Resistance | 2 | 2018 | 669 | 0.15 | Why? |
| Laser Therapy | 1 | 2018 | 158 | 0.15 | Why? |
| Immunocompetence | 1 | 2017 | 280 | 0.15 | Why? |
| Erythema Multiforme | 1 | 2018 | 172 | 0.15 | Why? |
| Diagnosis, Differential | 2 | 2020 | 7220 | 0.15 | Why? |
| Biological Factors | 1 | 2018 | 276 | 0.14 | Why? |
| Tacrolimus | 1 | 2018 | 435 | 0.14 | Why? |
| Hyperbaric Oxygenation | 1 | 2018 | 268 | 0.14 | Why? |
| Dermoscopy | 1 | 2017 | 346 | 0.13 | Why? |
| Lung Neoplasms | 3 | 2019 | 3228 | 0.13 | Why? |
| Anticonvulsants | 1 | 2018 | 634 | 0.12 | Why? |
| Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 896 | 0.12 | Why? |
| Anti-Infective Agents, Local | 1 | 2018 | 520 | 0.11 | Why? |
| Neoplasms | 1 | 2020 | 17251 | 0.11 | Why? |
| Brain Neoplasms | 1 | 2018 | 669 | 0.11 | Why? |
| Exanthema | 1 | 2020 | 1097 | 0.10 | Why? |
| Hand Disinfection | 1 | 2020 | 1671 | 0.10 | Why? |
| Endothelium, Vascular | 1 | 2021 | 1751 | 0.10 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 1454 | 0.09 | Why? |
| Telemedicine | 4 | 2020 | 25032 | 0.09 | Why? |
| Ambulatory Care Facilities | 1 | 2020 | 2063 | 0.09 | Why? |
| Italy | 7 | 2020 | 38444 | 0.09 | Why? |
| Patient Satisfaction | 1 | 2020 | 2517 | 0.08 | Why? |
| Arthritis, Rheumatoid | 1 | 2020 | 2043 | 0.08 | Why? |
| Dietary Supplements | 1 | 2018 | 2251 | 0.08 | Why? |
| Communicable Diseases, Emerging | 1 | 2020 | 2523 | 0.07 | Why? |
| Health Services Needs and Demand | 1 | 2020 | 3419 | 0.07 | Why? |
| Biological Products | 1 | 2020 | 2331 | 0.07 | Why? |
| Drug Therapy, Combination | 4 | 2019 | 7268 | 0.07 | Why? |
| Anti-Bacterial Agents | 4 | 2019 | 10083 | 0.07 | Why? |
| Psoriasis | 1 | 2019 | 1739 | 0.07 | Why? |
| Anti-Inflammatory Agents | 2 | 2019 | 6153 | 0.06 | Why? |
| Humans | 27 | 2021 | 930598 | 0.06 | Why? |
| Male | 14 | 2021 | 367725 | 0.06 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.06 | Why? |
| Pandemics | 6 | 2020 | 389249 | 0.06 | Why? |
| Administration, Oral | 2 | 2019 | 2340 | 0.06 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.06 | Why? |
| Infection Control | 2 | 2020 | 23131 | 0.05 | Why? |
| Triage | 1 | 2020 | 7151 | 0.05 | Why? |
| Isotretinoin | 1 | 2020 | 58 | 0.05 | Why? |
| Capsicum | 1 | 2018 | 9 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2018 | 6331 | 0.05 | Why? |
| Travel | 1 | 2018 | 7220 | 0.05 | Why? |
| Inositol | 1 | 2018 | 28 | 0.05 | Why? |
| Skin Cream | 1 | 2018 | 66 | 0.05 | Why? |
| Drug Combinations | 2 | 2018 | 3852 | 0.05 | Why? |
| Adult | 9 | 2020 | 244371 | 0.04 | Why? |
| Female | 12 | 2020 | 380317 | 0.04 | Why? |
| Ultraviolet Therapy | 1 | 2019 | 138 | 0.04 | Why? |
| Folic Acid | 1 | 2018 | 172 | 0.04 | Why? |
| Injections, Subcutaneous | 1 | 2019 | 647 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 9335 | 0.04 | Why? |
| Axilla | 1 | 2018 | 198 | 0.04 | Why? |
| Administration, Topical | 1 | 2018 | 272 | 0.04 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.04 | Why? |
| Liposomes | 1 | 2018 | 334 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Energy Intake | 1 | 2018 | 323 | 0.04 | Why? |
| TOR Serine-Threonine Kinases | 1 | 2018 | 385 | 0.04 | Why? |
| Magnesium | 1 | 2018 | 290 | 0.04 | Why? |
| Surveys and Questionnaires | 2 | 2020 | 43792 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.04 | Why? |
| Treatment Outcome | 5 | 2021 | 51732 | 0.04 | Why? |
| Office Visits | 1 | 2020 | 489 | 0.04 | Why? |
| Kenya | 1 | 2018 | 887 | 0.04 | Why? |
| Adolescent | 6 | 2020 | 86841 | 0.03 | Why? |
| Severity of Illness Index | 5 | 2020 | 48226 | 0.03 | Why? |
| Young Adult | 6 | 2020 | 93724 | 0.03 | Why? |
| Syndrome | 1 | 2018 | 1310 | 0.03 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.03 | Why? |
| Middle Aged | 6 | 2020 | 270681 | 0.03 | Why? |
| Dermatologic Agents | 1 | 2019 | 489 | 0.03 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 1316 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.03 | Why? |
| Waiting Lists | 1 | 2020 | 1388 | 0.03 | Why? |
| Diagnostic Errors | 1 | 2018 | 865 | 0.03 | Why? |
| Fatal Outcome | 1 | 2021 | 3438 | 0.03 | Why? |
| Aged | 4 | 2020 | 215776 | 0.03 | Why? |
| Telephone | 1 | 2020 | 1705 | 0.03 | Why? |
| Metabolic Syndrome | 1 | 2018 | 810 | 0.03 | Why? |
| Physician-Patient Relations | 1 | 2020 | 1266 | 0.02 | Why? |
| Case-Control Studies | 2 | 2018 | 17671 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.02 | Why? |
| Australia | 1 | 2020 | 6306 | 0.02 | Why? |
| Chronic Disease | 1 | 2020 | 5139 | 0.02 | Why? |
| Prospective Studies | 2 | 2020 | 43301 | 0.02 | Why? |
| Retrospective Studies | 3 | 2020 | 105322 | 0.02 | Why? |
| Referral and Consultation | 1 | 2020 | 4816 | 0.02 | Why? |
| Glucocorticoids | 1 | 2018 | 4431 | 0.01 | Why? |
| Medical Oncology | 1 | 2018 | 3826 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2021 | 11041 | 0.01 | Why? |
| Quality of Life | 1 | 2019 | 9820 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.01 | Why? |
| Prevalence | 1 | 2018 | 25773 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2021 | 88759 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.01 | Why? |
| Risk Factors | 1 | 2018 | 71621 | 0.01 | Why? |
Annunziata's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(129)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(44)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_